ºÃÉ«ÏÈÉú

January 16, 2026

The AAN recently published a new position statement on biosimilar therapeutics, providing key considerations on payer-mandated switching from biologic to biosimilar therapeutics. You can read it online in

What are biologic and biosimilar therapeutics?

Biologic therapeutics are pharmaceuticals manufactured from natural and living sources like microorganisms or animal and plant cells and have already been approved by the FDA. Biologic therapeutics can be complex and hard to manufacture, making them much more expensive than other drugs.

Biosimilar therapeutics are made from the same types of natural sources as their biologic counterparts. According to the FDA, they provide the same treatment benefits, have the same possible side effects, and are given in the same strength and dosage. Because of their lower cost, insurance companies are more likely to cover biosimilar products than biologic products. 

What does the statement say?

The statement provides a framework of considerations to aid decision-making and use of biosimilar therapeutics. It details where interchangeability of a biosimilar therapeutic is not well studied, data from comparative effectiveness research is not available, and special considerations before payer-mandated switching from a biologic to biosimilar therapeutic.

While the statement’s intent isn’t encouraging the coverage and use of biologic therapeutics, it is intended to encourage adequate consideration of patient subpopulations for whom mandatory switching would be harmful.

“This position statement provides necessary guidance for conversations with policymakers and payers on the complicated subject of biosimilar therapeutics,” said Jonathan D. Santoro, MD, chair of the AAN Health Policy Subcommittee and lead author of the statement. “Clinical decisions must prioritize patient safety while balancing health system costs, and this framework also provides another tool to help clinicians choose the most appropriate therapies for their patients.”